Friday, July 10, 2026

pharma · Hypophosphatasia · Paroxysmal Nocturnal Hemoglobinuria

Alexion Europe SAS

Alexion Pharma Germany is a pharma organization headquartered in EU. Primary therapeutic focus areas include Hypophosphatasia, Paroxysmal Nocturnal Hemoglobinuria, Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN)

EU HQ
89 Employees
EMA registrant Type
Company details
Status
Public
HQ
EU
Employees
89
Programs
33
Drugs
40
Patents
0
Clinical program

Danicopan

Phase 1 · small molecule · Healthy

Danicopan for Healthy is a Phase 1 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

← All Alexion Europe SAS projects Phase 1 small molecule completed

Internal code ACH471-010

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Alexion Europe SAS
Phase
Phase 1
Modality
small_molecule
Indication
Healthy
Status
completed
Trials
1